Related Experiment Video
Updated: May 21, 2026

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
Published on: May 23, 2021
Epidemiological and clinical features of pyogenic spondylodiscitis
M Fantoni1, E M Trecarichi, B Rossi
1Institute of Infectious Diseases, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. m.fantoni@rm.unicatt.it
Insights
Pyogenic spondylodiscitis (PS) is a spinal infection affecting 0.4-2.4 per 100,000 annually in Europe. Staphylococcus aureus is the most common cause, with increasing incidence due to aging populations and medical advancements.
Area of Science:
- Infectious Diseases
- Orthopedics
- Spinal Surgery
Background:
- Pyogenic spondylodiscitis (PS) is a rare but significant infection, comprising 3-5% of osteomyelitis cases.
- Incidence is rising due to increased life expectancy, immunocompromised patients, IV drug use, and spinal procedures.
- Hematogenous spread is the most common transmission route for PS.
Purpose of the Study:
- To review the epidemiology, causative agents, clinical presentation, and outcomes of pyogenic spondylodiscitis.
- To highlight the increasing incidence and risk factors associated with PS.
- To inform clinicians about the diagnostic and management challenges of this infection.
Main Methods:
- Literature review of pyogenic spondylodiscitis cases.
- Analysis of epidemiological data and causative microorganisms.
- Summary of clinical symptoms, diagnostic findings, and treatment outcomes.
Main Results:
- Staphylococcus aureus is the most frequent pathogen (approx. 50%), followed by Gram-negative rods (7-33%) and Coagulase-negative staphylococci (5-16%).
- Key symptoms include severe back pain, often worse at night, and fever (approx. 50% of cases).
- Mortality rates range from 0-11%, with potential for long-term complications like neurological deficits and persistent pain.
Conclusions:
- PS incidence is increasing, necessitating awareness among healthcare providers.
- Prompt diagnosis and appropriate treatment are crucial to minimize morbidity and mortality.
- Continued research is needed to optimize management strategies for pyogenic spondylodiscitis.
Abstract:
Pyogenic spondylodiscitis (PS) is an uncommon but important infection, that represents 3-5% of all cases of osteomyelitis. The annual incidence in Europe has been estimated to be from 0.4 to 2.4/100,000. A has been reported, with peaks at age less than 20 years and in the group aged 50-70 years. The incidence of PS seems to be increasing in the last years as a result of the higher life expectancy of older patients with chronic debilitating diseases, the rise in the prevalence of immunosuppressed patients, intravenous drug abuse, and the increase in spinal instrumentation and surgery. PS is in most cases a hematogenous infection. Staphylococcus aureus is the most frequent causative microorganism, accounting for about one half of the cases of PS. Gram-negative rods are causative agents in 7-33% of PS cases. Coagulase-negative staphylococci (CoNS) have been reported in 5-16% of cases. Staphylococcus epidermidis is often related to post-operative infections and intracardiac device-related bacteremia. Unremitting back pain, characteristically worsening during the night, is the most common presenting symptom, followed by fever that is present in about one half of the cases. The mortality of PS ranges from 0 to 11%. In a significant number of cases, recrudescence, residual neurological defects or persistent pain may occur.
Related Concept Videos
Acute Pyelonephritis I: Introduction
Degenerative Disc Disease ll: Pathophysiology
Endocarditis II: Clinical Features of Infective Endocarditis
Atypical Pneumonia
Acute Pyelonephritis II: Diagnostic Studies and Management
Degenerative Disc Disease I: Introduction